Short description
Synthetic Biologics is a biotechnology company developing biologics for the prevention and treatment of serious infectious diseases.
Description
Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery-stage biotherapeutics for the treatment of phenylketonuria.
Last funding
No Way
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Rockville, Maryland, United States, North America
Founded on
January 1, 2001
Exited on
July 6, 2007
Went public on
July 6, 2007
Stock symbol
SYN
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccessforu, Absolutely Noaccess, Noway Youcantaccess, Noaccessforu
Sign in for full access
Founders
Khalid Islam